Promising novel therapies for relapsed and refractory testicular germ cell tumors.

abstract：:Prostate cancer is the most common solid-organ cancer affecting the male population. Men with metastatic prostate cancer treated with androgen ablation therapy often respond rapidly, with improvement in bone pain and decreases in serum prostate-specific antigen. However, almost all patients progress to the castrate-re...

journal_title：Expert review of anticancer therapy

authors： Rawlinson A,Mohammed A,Beatty J,Bell R,Miller M

更新日期：2012-04-01 00:00:00

abstract：:Borderline ovarian tumors (BOTs) are epithelial tumors of the ovaries characterized by cellular proliferation and nuclear atypia but without an infiltrative growth pattern. As they frequently affect younger patients the clinical management is complicated by considerations such as preserving fertility and reducing post...

journal_title：Expert review of anticancer therapy

authors： Trillsch F,Mahner S,Ruetzel J,Harter P,Ewald-Riegler N,Jaenicke F,du Bois A

更新日期：2010-07-01 00:00:00

abstract：:A large number of different 5-hydroxytryptamine (HT)(3) receptor antagonists have been marketed with the indication of preventing nausea and vomiting induced by chemotherapy--palonosetron is the most recently developed of these. Pharmacologic studies have revealed that palonosetron has a long half-life, a high affinit...

journal_title：Expert review of anticancer therapy

authors： Ruhlmann C,Herrstedt J

更新日期：2010-02-01 00:00:00

abstract：INTRODUCTION:Endometrial cancer is the most common gynecologic malignancy in the developed world, and its incidence is increasing. Mortality from this cancer has not improved in recent decades and is primarily driven by high-grade carcinomas that are more likely to present at an advanced stage and ultimately are more l...

journal_title：Expert review of anticancer therapy

authors： Connor EV,Rose PG

更新日期：2018-09-01 00:00:00

abstract：INTRODUCTION:Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immun...

journal_title：Expert review of anticancer therapy

authors： Kamath SD,Kalyan A,Benson AB 3rd

更新日期：2018-12-01 00:00:00

abstract：INTRODUCTION:Angiogenesis is a complex process regulated by several pro- and anti-angiogenic factors, thus the loss of its fine equilibrium plays a key role in colorectal cancer (CRC) development and progression. Therapeutic agents targeting VEGF/VEGFR signaling, the main regulator of this process, proved to be effecti...

journal_title：Expert review of anticancer therapy

authors： Battaglin F,Puccini A,Intini R,Schirripa M,Ferro A,Bergamo F,Lonardi S,Zagonel V,Lenz HJ,Loupakis F

更新日期：2018-03-01 00:00:00

abstract：INTRODUCTION:Immunotherapy has emerged as a major class in the therapeutic arsenal of multiple myeloma. Cell-based immunotherapy (CAR T-cells) and monoclonal antibody-based immunotherapy (naked monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell engagers) are the two cornerstones of this novel approa...

journal_title：Expert review of anticancer therapy

authors： Jullien M,Touzeau C,Moreau P

更新日期：2020-10-26 00:00:00

abstract：:The prospects for the treatment of metastatic melanoma are improving. Whereas previous scientific meetings dedicated to the treatment of metastatic melanoma patients were overshadowed by our inability to improve overall survival or lengthen the time to progression, the results presented at the most recent meetings are...

journal_title：Expert review of anticancer therapy

authors： van Kempen LC

更新日期：2011-06-01 00:00:00

abstract：:Anemia is a frequent problem in cancer patients, especially in those treated with chemotherapy, and has an important negative impact on quality of life. Red blood cell transfusions provide clear but rather temporary comfort. The development of erythropoietic stimulating agents (ESAs) led to a more durable anemia treat...

journal_title：Expert review of anticancer therapy

authors： Vansteenkiste J,Wauters I

更新日期：2007-10-01 00:00:00

abstract：:In this report, we first describe the history of transsphenoidal surgery. We further elaborate on three fundamental surgical anatomy principles of transsphenoidal surgery for pituitary adenomas. First, the pituitary gland and, therefore, pituitary adenomas are extra-arachnoid structures, therefore the operation should...

journal_title：Expert review of anticancer therapy

authors： Ciric IS,Zhao J

更新日期：2006-09-01 00:00:00

abstract：:Anticancer therapy relies on targeting highly proliferative cells. Commonly used chemotherapy does not selectively target individual cancer cells. The identification of distinct cancer stem cells that have the unique ability to engraft tumors and maintain cancer self-renewal may prove vital in the development of novel...

journal_title：Expert review of anticancer therapy

authors： Klotz D

更新日期：2013-04-01 00:00:00

abstract：:Regional lymph node irradiation is usually indicated in patients with positive node breast cancer. However, there are some controversies regarding the clinical benefits of adding regional nodal irradiation to whole-breast or thoracic-wall irradiation after breast surgery especially for patients with 1 to 3 positive ax...

journal_title：Expert review of anticancer therapy

authors： Marta GN,de Moraes FY

更新日期：2015-01-01 00:00:00

abstract：:The incidence of thyroid cancer is increasing by 4% per year. Thyroid cancer has become the eighth most common malignancy diagnosed in women. Papillary cancer accounts for 80% of all thyroid cancer. The management of papillary thyroid cancer is challenging, primarily because there have been no prospective randomized t...

journal_title：Expert review of anticancer therapy

authors： Rosenbaum MA,McHenry CR

更新日期：2009-03-01 00:00:00

abstract：:Although the general intent of treatment for patients with recurrent ovarian cancer is palliative, and cure does not seem to be a realistic objective in this setting, median overall survival is greater than 12 months in platinum-sensitive recurrent ovarian cancer. Patients with ovarian cancer can now expect that the t...

journal_title：Expert review of anticancer therapy

authors： Kose MF,Meydanli MM,Tulunay G

更新日期：2006-03-01 00:00:00

abstract：:Crizotinib (XALKORI™, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer. Optimizing the management of frequent crizotinib-related adverse events is crucial to ensure its continuous administration and reprodu...

journal_title：Expert review of anticancer therapy

authors： Girard N,Audigier-Valette C,Cortot AB,Mennecier B,Debieuvre D,Planchard D,Zalcman G,Moro-Sibilot D,Cadranel J,Barlési F

更新日期：2015-02-01 00:00:00

abstract：:Satraplatin is a novel, orally bioavailable, platinum anticancer drug. Platinum analogs form the mainstay of treatment for a number of cancers, including lung, ovarian, colorectal and head and neck cancer. A disadvantage of the currently marketed platinum analogs is that they must all be administered via intravenous i...

journal_title：Expert review of anticancer therapy

authors： Choy H

更新日期：2006-07-01 00:00:00

abstract：:The failure of conventional chemotherapy to improve survival in a large percentage of patients with advanced solid tumors has prompted the development of alternative anticancer approaches. Conventional allogeneic hematopoietic stem cell transplantation (HSCT) relies on myeloablative conditioning to eradicate the under...

journal_title：Expert review of anticancer therapy

authors： Espinoza-Delgado I,Childs RW

更新日期：2004-10-01 00:00:00

abstract：:Today dermoscopy is standard-of-care in the diagnosis and management of patients with benign and malignant skin tumors because it increases the diagnostic accuracy of skin lesions compared to the naked-eye examination up to 25%. Despite its role in the routine dermato-oncology, it increasingly gained interest as a bri...

journal_title：Expert review of anticancer therapy

authors： Woltsche N,Schwab C,Deinlein T,Hofmann-Wellenhof R,Zalaudek I

更新日期：2016-05-01 00:00:00

abstract：INTRODUCTION:The therapeutic armamentarium for advanced soft tissue sarcoma (STS) has increased over the last few years. Doxorubicin monotherapy or in combination is now the established first line treatment. Beyond first line treatment, no standard therapy has been established. Novel drugs have reached the late-clinica...

journal_title：Expert review of anticancer therapy

authors： Skafida E,Kokkali S,Nikolaou M,Digklia A

更新日期：2017-06-01 00:00:00

abstract：:Limb-salvage surgery plays a major role in the management of patients with osteosarcoma. As prognosis improves, reconstructive options have come under greater scrutiny with regard to their durability and functionality. The advent of computer navigation-guided reconstruction is discussed in detail, along with methods b...

journal_title：Expert review of anticancer therapy

authors： Mangat KS,Jeys LM,Carter SR

更新日期：2011-02-01 00:00:00

abstract：:Since its introduction almost 40 years ago, intravesical BCG for non-muscle invasive bladder cancer remains one of the most successful cancer immunotherapies. However, up to 40% of patients will progress after BCG therapy and develop invasive bladder cancer. Despite its extensive clinical use, we are only beginning to...

journal_title：Expert review of anticancer therapy

authors： Wu Y,Enting D,Rudman S,Chowdhury S

更新日期：2015-05-01 00:00:00

abstract：:Many solid tumors, including breast and prostate cancer, metastasize to bone, thereby putting patients at high risk for developing skeletal complications including pathologic fracture, spinal cord compression and debilitating bone pain. Patients often live for many years after developing bone metastasis, a fact that h...

journal_title：Expert review of anticancer therapy

authors： Gulley J,Dahut WL

更新日期：2005-04-01 00:00:00

abstract：:Positron emission tomography (PET) is a functional diagnostic imaging technique that provides very different information from that obtainable with other imaging modalities. The most widely used radiotracer is F-18 fluoro-2-deoxy-D-glucose (FDG), which is an analog of glucose. The FDG uptake in cells is directly propor...

journal_title：Expert review of anticancer therapy

authors： Kumar R,Chauhan A,Vellimana AK,Chawla M

更新日期：2006-08-01 00:00:00

abstract：:We performed a meta-analysis to assess whether blood can be substituted for tumor tissue in K-ras mutation testing. PubMed, EMBASE, MEDLINE, and BIOSIS databases were searched. Twenty-three studies including 1261 patients were included. The pooled overall sensitivity, specificity, and concordance rate were 0.69 (95% C...

journal_title：Expert review of anticancer therapy

authors： Li Y,Fu XH,Yuan JQ,Yang ZY,Mao C,Dong XM,Tang JL,Wang SY

更新日期：2015-06-01 00:00:00

abstract：:Cardiac toxicity is one of the most important long-term toxicities experienced by cancer survivors so that survival rate due to anticancer therapy may be negatively affected due to cardiac complications. Thus, the search for novel methods to lower the incidence of treatment-related cardiotoxicity is a priority for all...

journal_title：Expert review of anticancer therapy

authors： Abdel-Rahman O,Alorabi M

更新日期：2015-01-01 00:00:00

abstract：:Colorectal cancer (CRC) is the third most common malignancy and cause of death from cancer among adults worldwide. In recent years, the use of 5-fluorouracil-based regimens in combination with molecularly targeted agents has greatly expanded treatment options for patients with metastatic disease. With a more capillary...

journal_title：Expert review of anticancer therapy

authors： Ribecco AS,Pino MS,Cipriani G,Marinozzi C,Fioretto L

更新日期：2013-10-01 00:00:00

abstract：:Until now, no effective systemic treatment options have been available for patients with unresectable advanced hepatocellular carcinoma (HCC). In the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP), patients with unresectable advanced HCC with Child-Pugh liver function class A and who had not...

journal_title：Expert review of anticancer therapy

authors： Rimassa L,Santoro A

更新日期：2009-06-01 00:00:00

abstract：:Introduction: Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and the third largest cause of cancer-relateddeaths worldwide. Potentially curative treatments (surgical resection, radiofrequency or liver transplantation) are only available for few patients, while transarterial chemoembolizat...

journal_title：Expert review of anticancer therapy

authors： Casadei-Gardini A,Orsi G,Caputo F,Ercolani G

更新日期：2020-01-01 00:00:00

abstract：:Proteasome inhibition has been shown to be an effective strategy for the treatment of multiple myeloma, as demonstrated by the clinical activity of the first-in-class agent bortezomib. Recently, the second-generation proteasome inhibitor carfilzomib has been approved in the USA in the relapsed and refractory setting, ...

journal_title：Expert review of anticancer therapy

authors： McBride A,Ryan PY

更新日期：2013-03-01 00:00:00

abstract：:Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/o...

journal_title：Expert review of anticancer therapy

authors： Jimeno A,Carducci M

更新日期：2005-06-01 00:00:00